Compare ProShares Ultra Bitcoin ETF (BITU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bitcoin ETF vs Sanofi SA — how do they compare? ProShares Ultra Bitcoin ETF trades at $9.36, while Sanofi SA trades at $43.51 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while ProShares Ultra Bitcoin ETF pays none, and Sanofi SA is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITU | SNY | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.41 | $52.34 |
52-Week Low | $8.12 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITU trades at $9.64, up 1.69% with neutral technical signals. The stock shows mixed momentum with bullish moving averages but neutral oscillators. Recent dividend payments of $0.01-$0.02 provide shareholder returns, though key financial ratios remain undisclosed in current filings.
The outlook remains cautious with technical indicators showing limited directional bias. Investment opportunity exists through dividend yield, but risks include volatility and lack of clear fundamental data. Analyst sentiment appears neutral with equal buy/sell recommendations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
